FindTrial
Sign In

Post marketing study of sivelestat sodium hydrate for acute lung injury associated with systemic inflammatory response syndrome

Post marketing study of sivelestat sodium hydrate for acute lung injury associated with systemic inflammatory response syndrome

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080220086
Enrollment
Unknown
Registered
2005-09-12
Start date
2005-09-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lung injury (ALI) associated with systemic inflammatory response syndrome (SIRS)

Interventions

investigational material(s) Generic name etc : Sivelestat sodium hydrate INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administratio

Sponsors

ONO PHARMACEUTICAL CO.,LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Male and female patients with ALI associated with SIRS aged over 18 years old are included.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy and safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026